The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index; 26 of the 61 sources its claims cite were checked for support.
Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response
Open accessAbstract
Background: Psychedelic-assisted therapy (PAT) is permitted in Switzerland under its limited medical use program. Data from patients in this program represent a unique opportunity to analyze the real-world practice of PAT. Aims: This study compared the subjective effects of lysergic acid diethylamide (LSD) and psilocybin between patients undergoing PAT and healthy volunteers. For the patients, it also investigated the relationship between antidepressant effects and six measures of acute drug effects. Methods: We compared data on acute psychedelic drug effects between 28 PAT patients with data from 28 healthy participants who participated in a randomized, double-blind crossover trial. All participants received varying doses of psilocybin and LSD. Subjective effects were assessed on an hourly basis during the acute drug effects, and the Mystical Experience Questionnaire (MEQ) was completed retrospectively. For patients, depressive symptoms were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). Results: Ratings of overall drug effect and mystical experience were similar across groups. Compared with healthy controls, patients reported lower ratings of ego dissolution. Patients showed a significant decrease in MADRS scores, and the greatest predictor of antidepressant outcome was relaxation during the PAT session. We did not observe a relationship between mystical-type experiences and antidepressant effects. Most patients experienced mild adverse effects which resolved within 48 h. Conclusion: PAT reduced depressive symptoms in this heterogeneous patient group. Patients may experience more challenging psychedelic effects and reduced ego dissolution. Hourly assessment of drug effects may predict clinical outcomes better than retrospectively assessed mystical experiences, and the impact of relaxation during PAT should be investigated further. © The Author(s) 2024.
Overview
CoChat Summary
## TL;DR
In this naturalistic Swiss PAT study, patients receiving LSD or psilocybin showed a significant reduction in depressive symptoms, and the strongest predictor of immediate antidepressant response was relaxation during the session. Compared with healthy volunteers, patients reported less ego dissolution, while retrospective mystical-experience scores were not associated with antidepressant effects.
## Key findings
- In 21 patients with treatment-resistant depression, mean MADRS score was 20.9 at baseline and fell by 29% (6.2 points) immediately after PAT; the improvement remained significant at follow-up about 7.7 days later.
- Across 55 treatment sessions in 28 patients, subjective “any drug effect” ratings increased with dose (F(5, 30) = 6.884, p < 0.001).
- Compared with 28 healthy participants, patients had significantly lower ego dissolution ratings (β = −183.50, SE = 36.01, p < 0.001); overall drug effect and good drug effect were not significantly different, and bad drug effect was higher but not statistically significant (p = 0.09).
- For immediate antidepressant response, real-time acute effect ratings explained 28% of the variance in MADRS improvement, while MEQ scores explained 4%; among the real-time ratings, relaxation was the only significant predictor (β = −0.04, SE = 0.01, p = 0.03).
## Methods
- Naturalistic, open-label PAT data from 28 Swiss patients undergoing 55 sessions with LSD or psilocybin were compared with data from 28 healthy volunteers in a randomized, double-blind crossover trial.
- Patients were mostly residents of Switzerland, average age 49, and 78.6% were taking psychiatric medications; 24/28 had treatment-resistant major depressive disorder and the rest had OCD, bipolar disorder, or social anxiety.
- Acute effects were rated hourly in patients and at least hourly in healthy participants; analyses used linear mixed-effects models, with AUC for acute ratings and MADRS used to assess depressive symptoms.
## Limitations
- The paper states that the patient data were heterogeneous, open-label, non-randomized, and uncontrolled, and that all patients were in psychotherapy before and after dosing, limiting causal inference.
- Follow-up times were relatively short, the patient sample was relatively small and underpowered for some analyses, and some MADRS and MEQ data were missing.
- The paper notes that some dose groups were extremely small, flexible dosing limited dose comparability, and the patient and healthy samples came from two different hospitals; these are evident limitations from the text.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
20 Valid · 0 Not valid · 22 Not checked · 75 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Psychedelic-assisted therapy (PAT) with psilocybin and lysergic acid diethylamide (LSD) has demonstrated efficacy in the treatment of depression, anxiety, and some other neuropsychiatric disorders”
§ Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response > Introduction Psychedelic-assisted therapy (PAT) with psilocybin and lysergic acid diethylamide (LSD) has demonstrated efficacy in the treatment of depression, anxiety, and some other neuropsychiatric disorders (Gasser et al., 2014; Goodwin et al., 2022; Holze et al., 2023b; Raison et al., 2023; von Rotz et al., 2023). Given promising preliminary data, PAT has been conducted in Switzerland under its limited medical use program from 1988 to 1993, and again since 2014 (Calder and Hasler, 2023a). This program allows PAT with LSD, psilocybin, or the empathogen 3,4-methylenedioxymethamphetamine (MDMA) under the supervision of a licensed physician for patients with an applicable treatment-resistant diagnosis. Eligible diagnoses include post-traumatic stress disorder (Mitchell et al., 2023), major depressive disorder (Galvao-Coelho et al., 2021), anxiety disorders (Holze et al., 2023b), substance use disorders (Bogenschutz et al., 2022), obsessive-compulsive disorder (Moreno et al., 2006), eating disorders (Calder et al., 2023), and others. Patients may undergo multiple sessions if needed, typically at intervals of several weeks or months, and this flexible dosing schedule is an important difference between naturalistic PAT and controlled trials. Patients are also not required to taper off psychiatric medications before undergoing PAT when the risk of unfavorable drug interactions appears low (Becker et al., 2022; Malcolm and Thomas, 2022). In addition, patients who positively responded to PAT in clinical trials sponsored by academia or industry may continue PAT within the limited medical use program, fulfilling recent recommendations for ethical continuing care after clinical trials of PAT (Jacobs et al., 2024). Data from Swiss PAT reflect real-world variation in substances, doses, diagnoses, treatment duration, and concomitant medications, and can thus offer valuable insights into how PAT is already practiced outside of controlled clinical trials. Many PAT practitioners regard the subjective acute psychedelic effects as important for the therapeutic outcome (Yaden and Griffiths, 2021). However, there is some debate about precisely which effects are important. One view is that mystical-type experiences, commonly measured at the end of a PAT session with the Mystical Experience Questionnaire (MEQ), are particularly important for therapeutic effects (Griffiths et al., 2006, 2016; Liechti et al., 2017; Ross et al., 2016). A “complete” mystical experience involves feelings of profound unity and sacredness, euphoria, and transcendence of time and space, as well as a sense of experiencing profound truth one struggles to capture in words (i.e., ineffability; Barrett et al., 2015). The association between mystical-type experiences and clinical outcomes has been shown in studies of psilocybin-assisted therapy for depression, end-of-life distress, and substance use disorders, as well as in LSD-assisted therapy for anxiety (Holze et al., 2023b; Ko et al., 2022). However, other studies have not found associations between symptom improvement and mystical-type experiences (Agin-Liebes et al., 2020; Gukasyan et al., 2022; Sloshower et al., 2023). Some scholars argue that the acceptance of mystical-type experiences as a defining therapeutic mechanism in PAT is too hasty and that the role of other psychedelic effects is in danger of being overlooked (Sanders and Zijlmans, 2021). Previous research has also investigated whether the intensity of pleasant and unpleasant psychedelic effects is related to therapeutic outcomes. One meta-analysis found that the overall intensity of a psychedelic experience was the best predictor of therapeutic effects (Romeo et al., 2021). In general, overall positively experienced psychedelic effects also seem to correlate positively with long-term therapeutic outcomes (Holze et al., 2023b; Roseman et al., 2017). The pattern is less clear for acutely unpleasant effects or “challenging experiences,” whose relationship with therapeutic efficacy likely depends on how they are resolved (Carhart-Harris et al., 2018). In addition, the experience of ego dissolution is considered important in PAT by some practitioners. Ego dissolution is the temporary full or partial cessation of the subjective sense of self (Nour et al., 2016). Many consider it to be a typical effect of both LSD and psilocybin (Mason et al., 2020; Tagliazucchi et al., 2016), particularly at higher doses (Holze et al., 2021). In supportive settings, ego dissolution appears to be related to subsequent reductions in symptoms of depression and anxiety (Kiraga et al., 2022; van Oorsouw et al., 2022). Mystical-type experiences, ego dissolution, and other psychedelic drug effects are usually measured retrospectively, after a return to normal consciousness (Schmid et al., 2021; Schmidt and Berkemeyer, 2018). However, it is also feasible to obtain measures of psychedelic drug effects in real time using relatively simple measures in the form of visual analog scales (Holze et al., 2022b) or verbal Likert scales (Vogt et al., 2023). Many studies in healthy volunteers have asked participants to rate the intensity of psychedelic effects at regular intervals during the experience, including the overall intensity of drug effects, positive and negative effects, and ego dissolution (Holze et al., 2021; Ley et al., 2023; Straumann et al., 2023; Vogt et al., 2023). Real-time data may be valuable in clinical settings as well, for two main reasons. First, there can be significant variation in how people view an experience while it is happening and after it has ended (Oishi, 2016). It is thus interesting to assess whether real-time ratings correlate with therapeutic outcomes in the same way that retrospective ratings, such as MEQ scores, appear to do. Notably, previous research suggests that retrospectively measured effects of LSD at 10 or 24 h post-dosing were very similar to those measured during the peak response at 3 h (Liechti et al., 2017). Second, real-time ratings can give PAT practitioners valuable and immediate feedback on how a psychedelic experience is progressing in a clear and minimally intrusive way while there is still time to influence the experience if necessary. People undergoing psychedelic treatments may not spontaneously articulate how they are feeling, and simple verbal feedback about the overall intensity, valence, and other effects can provide valuable information about the progress and nature of patients’ experiences and the therapeutic process. In the present study, we analyze naturalistic data from PAT with psilocybin and LSD from the Swiss limited medical use program together with data from a randomized controlled crossover trial with psilocybin and LSD in healthy participants (Holze et al., 2022b). In the patient group, we investigate dose–response relationships of different doses of LSD and psilocybin on subjective effects, as well as the relationship between subjective drug effects and depressive symptoms. In addition, we investigate whether subjective effects differ between patients and healthy participants receiving the same well-characterized drug formulation and dose (Holze et al., 2019, 2023a), as well as the relationship between real-time assessments of subjective effects and retrospective MEQ scores. Finally, we report the adverse effects of PAT in the patient group. These data offer valuable insights into PAT in real-world clinical practice outside of controlled trials.
What the sources say
- Partly supportedcites Gasser et al., 2014 sourceExperimental — accuracy not yet measured
The Conclusions (page unavailable) report positive trends in reduced anxiety after LSD-assisted psychotherapy for people with life-threatening illnesses and describe a psilocybin study as promising. The Abstract reports a historical finding of reduced depression in advanced-stage cancer patients. These qualified findings do not establish efficacy across depression, anxiety, and other neuropsychiatric disorders as the citing sentence suggests. (LLM, conf=0.88)
- Partly supportedcites Goodwin et al., 2022 sourceExperimental — accuracy not yet measured
The Abstract reports that a 25-mg dose of psilocybin given with psychological support reduced depression scores more than a 1-mg dose over three weeks in adults with treatment-resistant depression. It also cites preliminary studies involving depression and anxiety in patients with life-threatening cancer, but this trial did not test anxiety treatment. The cited paper provides no evidence about LSD or efficacy for other neuropsychiatric disorders, and it says larger, longer trials are needed to determine psilocybin’s efficacy and safety. (LLM, conf=0.88)
- Not matchedcites Holze et al., 2023b
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, it is also feasible to obtain measures of psychedelic drug effects in real time using relatively simple measures in the form of visual analog scales (Holze et al., 2022b) or verbal Likert scales (Vogt et al., 2023).”
§ Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response > Introduction Psychedelic-assisted therapy (PAT) with psilocybin and lysergic acid diethylamide (LSD) has demonstrated efficacy in the treatment of depression, anxiety, and some other neuropsychiatric disorders (Gasser et al., 2014; Goodwin et al., 2022; Holze et al., 2023b; Raison et al., 2023; von Rotz et al., 2023). Given promising preliminary data, PAT has been conducted in Switzerland under its limited medical use program from 1988 to 1993, and again since 2014 (Calder and Hasler, 2023a). This program allows PAT with LSD, psilocybin, or the empathogen 3,4-methylenedioxymethamphetamine (MDMA) under the supervision of a licensed physician for patients with an applicable treatment-resistant diagnosis. Eligible diagnoses include post-traumatic stress disorder (Mitchell et al., 2023), major depressive disorder (Galvao-Coelho et al., 2021), anxiety disorders (Holze et al., 2023b), substance use disorders (Bogenschutz et al., 2022), obsessive-compulsive disorder (Moreno et al., 2006), eating disorders (Calder et al., 2023), and others. Patients may undergo multiple sessions if needed, typically at intervals of several weeks or months, and this flexible dosing schedule is an important difference between naturalistic PAT and controlled trials. Patients are also not required to taper off psychiatric medications before undergoing PAT when the risk of unfavorable drug interactions appears low (Becker et al., 2022; Malcolm and Thomas, 2022). In addition, patients who positively responded to PAT in clinical trials sponsored by academia or industry may continue PAT within the limited medical use program, fulfilling recent recommendations for ethical continuing care after clinical trials of PAT (Jacobs et al., 2024). Data from Swiss PAT reflect real-world variation in substances, doses, diagnoses, treatment duration, and concomitant medications, and can thus offer valuable insights into how PAT is already practiced outside of controlled clinical trials. Many PAT practitioners regard the subjective acute psychedelic effects as important for the therapeutic outcome (Yaden and Griffiths, 2021). However, there is some debate about precisely which effects are important. One view is that mystical-type experiences, commonly measured at the end of a PAT session with the Mystical Experience Questionnaire (MEQ), are particularly important for therapeutic effects (Griffiths et al., 2006, 2016; Liechti et al., 2017; Ross et al., 2016). A “complete” mystical experience involves feelings of profound unity and sacredness, euphoria, and transcendence of time and space, as well as a sense of experiencing profound truth one struggles to capture in words (i.e., ineffability; Barrett et al., 2015). The association between mystical-type experiences and clinical outcomes has been shown in studies of psilocybin-assisted therapy for depression, end-of-life distress, and substance use disorders, as well as in LSD-assisted therapy for anxiety (Holze et al., 2023b; Ko et al., 2022). However, other studies have not found associations between symptom improvement and mystical-type experiences (Agin-Liebes et al., 2020; Gukasyan et al., 2022; Sloshower et al., 2023). Some scholars argue that the acceptance of mystical-type experiences as a defining therapeutic mechanism in PAT is too hasty and that the role of other psychedelic effects is in danger of being overlooked (Sanders and Zijlmans, 2021). Previous research has also investigated whether the intensity of pleasant and unpleasant psychedelic effects is related to therapeutic outcomes. One meta-analysis found that the overall intensity of a psychedelic experience was the best predictor of therapeutic effects (Romeo et al., 2021). In general, overall positively experienced psychedelic effects also seem to correlate positively with long-term therapeutic outcomes (Holze et al., 2023b; Roseman et al., 2017). The pattern is less clear for acutely unpleasant effects or “challenging experiences,” whose relationship with therapeutic efficacy likely depends on how they are resolved (Carhart-Harris et al., 2018). In addition, the experience of ego dissolution is considered important in PAT by some practitioners. Ego dissolution is the temporary full or partial cessation of the subjective sense of self (Nour et al., 2016). Many consider it to be a typical effect of both LSD and psilocybin (Mason et al., 2020; Tagliazucchi et al., 2016), particularly at higher doses (Holze et al., 2021). In supportive settings, ego dissolution appears to be related to subsequent reductions in symptoms of depression and anxiety (Kiraga et al., 2022; van Oorsouw et al., 2022). Mystical-type experiences, ego dissolution, and other psychedelic drug effects are usually measured retrospectively, after a return to normal consciousness (Schmid et al., 2021; Schmidt and Berkemeyer, 2018). However, it is also feasible to obtain measures of psychedelic drug effects in real time using relatively simple measures in the form of visual analog scales (Holze et al., 2022b) or verbal Likert scales (Vogt et al., 2023). Many studies in healthy volunteers have asked participants to rate the intensity of psychedelic effects at regular intervals during the experience, including the overall intensity of drug effects, positive and negative effects, and ego dissolution (Holze et al., 2021; Ley et al., 2023; Straumann et al., 2023; Vogt et al., 2023). Real-time data may be valuable in clinical settings as well, for two main reasons. First, there can be significant variation in how people view an experience while it is happening and after it has ended (Oishi, 2016). It is thus interesting to assess whether real-time ratings correlate with therapeutic outcomes in the same way that retrospective ratings, such as MEQ scores, appear to do. Notably, previous research suggests that retrospectively measured effects of LSD at 10 or 24 h post-dosing were very similar to those measured during the peak response at 3 h (Liechti et al., 2017). Second, real-time ratings can give PAT practitioners valuable and immediate feedback on how a psychedelic experience is progressing in a clear and minimally intrusive way while there is still time to influence the experience if necessary. People undergoing psychedelic treatments may not spontaneously articulate how they are feeling, and simple verbal feedback about the overall intensity, valence, and other effects can provide valuable information about the progress and nature of patients’ experiences and the therapeutic process. In the present study, we analyze naturalistic data from PAT with psilocybin and LSD from the Swiss limited medical use program together with data from a randomized controlled crossover trial with psilocybin and LSD in healthy participants (Holze et al., 2022b). In the patient group, we investigate dose–response relationships of different doses of LSD and psilocybin on subjective effects, as well as the relationship between subjective drug effects and depressive symptoms. In addition, we investigate whether subjective effects differ between patients and healthy participants receiving the same well-characterized drug formulation and dose (Holze et al., 2019, 2023a), as well as the relationship between real-time assessments of subjective effects and retrospective MEQ scores. Finally, we report the adverse effects of PAT in the patient group. These data offer valuable insights into PAT in real-world clinical practice outside of controlled trials.
What the sources say
- Not matchedcites Holze et al., 2022b
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Supportedcites Vogt et al., 2023 source
The Methods and Materials section (“Subjective drug effects and effect durations”; page not supplied) says participants repeatedly rated DMT effects during the session using verbal 0–10 Likert scales. The Results section reports effects over time from those scales. Vogt et al. therefore supports the verbal-Likert-scale part of the citing sentence; the visual-analog-scale part is attributed to a different source. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Controlled clinical trials with psilocybin, as well as other psychedelics, have occasionally reported increases in suicidality after treatment, sometimes with extremely brief information about treatment-relatedness (Breeksema et al., 2022; Goodwin et al., 2022).”
§ Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response > Discussion
What the sources say
- Partly supportedcites Breeksema et al., 2022 sourceExperimental — accuracy not yet measured
The Discussion’s “Suicidality” section reports preliminary psilocybin trial results suggesting higher suicidality rates in active-dose groups than in the low-dose group, while cautioning that interpretation awaits peer-reviewed results. It also reports suicidal ideation and behavior in MDMA studies, but says rates were lower than or similar to controls; it does not establish an increase for other psychedelics. The suicide 11 days after a placebo-like psilocybin dose was reported as unrelated to the study. (LLM, conf=0.86)
- Supportedcites Goodwin et al., 2022 source
The Safety section reports worsening of suicidal state from baseline to week 3 in all three psilocybin dose groups and describes suicidal ideation and behavior after dosing. This supports the psilocybin-trial portion of the jointly cited sentence; Goodwin et al. do not need to establish the separate claim about other psychedelics. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistently, escitalopram and psilocybin co-administration were well tolerated (Becker et al., 2022).”
§ Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response > Discussion
What the sources say
- Supportedcites Becker et al., 2022 source
The Conclusion states that escitalopram and psilocybin can be safely administered together. The Results (Autonomic and adverse effects) report that escitalopram pretreatment reduced acute adverse effects associated with psilocybin, supporting the claim that the combination was well tolerated in this study of healthy subjects. (LLM, conf=0.94)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The ability to relax oneself, especially in stressful situations, may be an important coping mechanism that promotes feelings of self-efficacy, which are often reduced in depression (Fung and White, 2012).”
§ Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response > Discussion
What the sources say
- Partly supportedcites Fung and White, 2012 sourceExperimental — accuracy not yet measured
Section 3.3.1 describes relaxation training as a coping skill that can increase self-control and self-efficacy, and Section 4.2 describes it as a self-administered stress-relief technique. The copy does not establish that self-efficacy is often reduced in depression or specifically assess relaxation during stressful situations. (LLM, conf=0.82)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
53 more claims
Create a free account to see all 117 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 45
- It may state two separate claims as one. 22
- The quote only partly states this claim. 3
Statistics recomputed
Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.
- ConsistentF(5, 30) = 6.884reported p < .001 · recomputed p < .001
“F(5, 30) = 6.884, p < .001”
- Consistentt(45.71) = 4.2reported p < .001 · recomputed p < .001
“t(45.71) = 4.2, p < .001”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Citations
Cites
Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835 · cited 1×
“1.35.1) (Bates et al., 2015; Dixon, 2003).”
InfluentialVEGAN, a package of R functions for community ecology
Dixon, P. (2003) · Journal of Vegetation Science · doi:10.1111/j.1654-1103.2003.tb02228.x · Cited by 6,824 · cited 1×
“1.35.1) (Bates et al., 2015; Dixon, 2003).”
InfluentialGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 2×
“…effect (Gasser et al., 2015; Schmid et al., 2021), although other studies do show correlations between MEQ30 scores and therapeutic effects in PAT for depression and anxiety disorders (Davis et al., 2021; Griffiths et al., 2016; Holze et al., 2023b; Ross et al., 2016; Roseman et al., 2017).”
BackgroundResultRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698 · cited 2×
“…effect (Gasser et al., 2015; Schmid et al., 2021), although other studies do show correlations between MEQ30 scores and therapeutic effects in PAT for depression and anxiety disorders (Davis et al., 2021; Griffiths et al., 2016; Holze et al., 2023b; Ross et al., 2016; Roseman et al., 2017).”
BackgroundResultGriffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 1×
“One view is that mystical-type experiences, commonly measured at the end of a PAT session with the Mystical Experience Questionnaire (MEQ), are particularly important for therapeutic effects (Griffiths et al., 2006, 2016; Liechti et al., 2017; Ross et al., 2016).”
BackgroundEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301 · cited 1×
“…effect (Gasser et al., 2015; Schmid et al., 2021), although other studies do show correlations between MEQ30 scores and therapeutic effects in PAT for depression and anxiety disorders (Davis et al., 2021; Griffiths et al., 2016; Holze et al., 2023b; Ross et al., 2016; Roseman et al., 2017).”
ResultHuman hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203 · cited 1×
“In addition, both antipsychotics and benzodiazepines can reduce the acute effects of psychedelics (Johnson et al., 2008).”
BackgroundSingle-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206443 · Cited by 1,167 · cited 2×
“Controlled clinical trials with psilocybin, as well as other psychedelics, have occasionally reported increases in suicidality after treatment, sometimes with extremely brief information about treatment-relatedness (Breeksema et al., 2022; Goodwin et al., 2022).”
BackgroundRoseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789 · cited 1×
“…stress disorder (Mitchell et al., 2023), major depressive disorder (Galvao-Coelho et al., 2021), anxiety disorders (Holze et al., 2023b), substance use disorders (Bogenschutz et al., 2022), obsessive-compulsive disorder (Moreno et al., 2006), eating disorders (Calder et al., 2023), and others.”
Background
Research works printed but not linked: 1
- Haden M, 2019, Manual for Psychedelic Guides
Cited by
Roméo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Bezo, A., Piolino, P., & Benyamina, A. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106086 · Cited by 67
Calder, A. E., & Hasler, G. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.091 · Cited by 28
Self-citationLiechti, M. E., Gasser, P., Aicher, H., Müller, F., Hawrot, T., & Schmid, Y. (2025) · Neuroscience Applied · doi:10.1016/j.nsa.2025.105525 · Cited by 24
Self-citationTraumatic Psychedelic Experiences
Calder, A. E., Diehl, V. J., & Hasler, G. (2025) · Current topics in behavioral neurosciences · doi:10.1007/7854_2025_579 · Cited by 21
Self-citationSeragnoli, F., Picard, F., Thorens, G., Buchard, A., Geyer, M., Abatista, A., Ponomarenko, P., Petignat, C., Riccardi, M., Bisson, M. D., et al. (2025) · Cognitive Therapy and Research · doi:10.1007/s10608-025-10588-z · Cited by 8
“/ “Eureka!” or insight experience, also definable as metacognitive feeling of epistemic gain It has nevertheless been argued that the mystical-type experience is not essential for psychotherapeutic outcomes in PAT (Calder et al., 2024; Gasser et al., 2015; Schmid et al., 2021).”
Metadata
- Authors
- Calder, A. E., Rausch, B., Liechti, M. E., Holze, F., & Hasler, G.
- Affiliations
- University of Freiburg (DE)
- Saarland University (DE)
- University of Basel (CH)
- Corresponding author
- Hasler, Gregor
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2024-09-20
- Volume
- 38
- Issue
- 10
- Pages
- 873-886
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC11487903
- OpenAlex
- W4402680012
- Cited by
- 20
- References
- 83
- Citations by year
- 2026: 10 · 2025: 9 · 2024: 1
- FWCI
- 9.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Psychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psychedelic therapy, psilocybin, lysergic acid diethylamide, depression, antidepressant response, subjective drug effects, relaxation, ego dissolution, mystical experience, adverse effects, real-world practice
- MeSH terms
- Adult, Antidepressive Agents, Depression, Double-Blind Method, Female, Hallucinogens, Humans, Lysergic Acid Diethylamide, Male, Middle Aged, Mysticism, Psilocybin, Psychiatric Status Rating Scales, Relaxation, Switzerland, Treatment Outcome, Cross-Over Studies, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response. https://app.cochat.ai/papers/10.1177/02698811241278873
- The paper
- Calder, A. E., Rausch, B., Liechti, M. E., Holze, F., & Hasler, G. (2024). Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response. Journal of Psychopharmacology. https://doi.org/10.1177/02698811241278873
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.